Management ideally done in consultation with heme/onc
Plasma exchange (plasmapheresis)
Replaces defective or insufficient ADAMTS-13 and clears vWF multimers
Transfusion of pRBCs (only severe bleeding)
Generally only indicated if plasma exchange cannot be performed immediately
FFP Transfusion
Contains ADAMTS-13
Should only be initiated if delay in plasmapheresis
Glucocorticoids
Consider 1 mg/kg prednisone PO or methylprednisolone 125 mg IV
Splenectomy - 2nd line therapy after stabilization
Inhibitor antibody is made in the spleen
Platelet transfusion is AVOIDED
Only used for life-threatening bleeding or intracranial hemorrhage under guidance from hematologist
Platelet infusion may lead to acutely worsened thrombosis, renal failure, and death
Replaces defective or insufficient ADAMTS-13 and clears vWF multimers
Generally only indicated if plasma exchange cannot be performed immediately
Contains ADAMTS-13
Should only be initiated if delay in plasmapheresis
Consider 1 mg/kg prednisone PO or methylprednisolone 125 mg IV
Inhibitor antibody is made in the spleen
Only used for life-threatening bleeding or intracranial hemorrhage under guidance from hematologist
Platelet infusion may lead to acutely worsened thrombosis, renal failure, and death
Thrombotic thrombocytopenic purpura
Other MAHAs 
Immune thrombocytopenic purpura
ITP
Disseminated intravascular coagulation
Sepsis
Heparin-Induced Thrombocytopenia 
SLE